Pharmalot Ed Silverman STAT Plus: Johnson & Johnson is fined $30 million for thwarting generics in France
First Opinion Dana P. Goldman and Tomas J. Philipson Biosimilars competition helps patients more than generic competition
Pharmalot Ed Silverman STAT Plus: Dozens of generic makers and pharmacies won’t face lawsuits over Zantac and cancer risks
Pharmalot Ed Silverman STAT Plus: Washington may become the second state to distribute its own generic drugs
Pharmalot Ed Silverman STAT Plus: To the delight of generic drug makers, federal appeals court tosses controversial ‘skinny labeling’ decision
Pharmalot Ed Silverman STAT Plus: U.S. drug prices were more than double those in dozens of countries in 2018
Pharmalot Ed Silverman STAT Plus: They did what? Celgene backs out of a $55 million deal to settle claims of thwarting generics
Pharmalot Ed Silverman STAT Plus: FDA bid to bolster generic competition and combat shortages isn’t working β yet
Pharmalot Ed Silverman STAT Plus: Pharmalittle: Pfizer to merge off-patent business with Mylan; conservatives try to sabotage Trump pricing plan
Pharmalot Ed Silverman STAT Plus: Generic drug price-fixing suit is akin to earlier case, but βon steroids,β Conn. prosecutor says
Pharmalot Ed Silverman STAT Plus: Two former pharma execs first to be charged in generic price-fixing probe